U.S. Drug Administration approves long-acting antibody AstraZeneca Evusheld (AZD7442)
AstraZeneca’s Evusheld is a long-acting combination of antibodies (tixagevimab and cilgavimab) approved by the U.S. Drug Administration (FDA) for emergency use to prevent COVID-19. The first shipments are expected to be available soon.
Related news
Are the drug and dietary supplement vending machines coming?
The soon-to-be widely available medicine vending machines, which are currently…
Read more >
Medicines, yes, but we don’t look for healing on the Internet
In the case of a health complaint they have not…
Read more >
BENU and Foglaljorvost.hu signed a cooperation agreement
Hungary’s best-known pharmacy network and the country’s largest healthcare appointment…
Read more >
More related news >
Related news
Nestlé Szerencs factory expands with new solar park
The 1.5 GW annual capacity solar park will come into…
Read more >
A new chapter has opened in the history of Pizza Hut: The restaurant chain can be renewed based on the Hungarian model
On September 12, the ribbon was cut on Pizza Hut’s…
Read more >
150 million bottles, jars and aluminum cans have already been returned in Lidl stores
Lidl Hungary has reached a milestone in its new return…
Read more >
){kind=link}